TGA Approval

BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial (347293)

ARTG ID

347293

ARTG Name

BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial

Sponsor

Cipla Australia Pty Ltd

ARTG Date

November 2, 2021

Registration Type

Medicine

Therapeutic Good Type

Medicine

Licence Status

Active

Licence Category

Registered

Sponsor Information

Sponsor Name

Sponsor Item Name

CIPLA AUSTRALIA PTY LTD

https://medical-cdn.nocode.com/drug_tga/5cec394d01c98455a17164dd48c8b2e5.pdf

https://medical-cdn.nocode.com/drug_tga/2b9b9c78adc0d3c494c4cb103aea3693.pdf

Ingredient Name

Bevacizumab

Empowering clinical research with data-driven insights and AI-powered tools.

BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial (347293) - TGA 批准文号 | MedPath